Department of Pediatric Medicine, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Behandlingsvagen 7, 416 50, Gothenburg, Sweden.
Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Box 426, 405 30, Gothenburg, Sweden.
Syst Rev. 2022 Mar 29;11(1):54. doi: 10.1186/s13643-022-01929-0.
Over the past decades, the survival rate for childhood cancer has greatly improved. However, the risk of late cardiac complications after cancer treatment remains high. Previous studies have shown that the risk for heart failure among childhood cancer survivors is significantly higher than that observed in varying control populations. The aim of this systematic review is to identify, critically appraise, and synthesize existing population-based studies reporting on the frequency of heart failure, both the incidence and prevalence, that may develop after treatment for childhood cancer.
The following databases will be searched from their inception date until May 17, 2021: MEDLINE, Embase, Scopus, CINAHL, CAB International, AMED, Global Health, PsycINFO, Web of Science, and Google Scholar. Population-based studies reporting on the incidence and/or prevalence of heart failure after the treatment of any type of childhood cancer will be included. The screening of articles, data extraction, and quality assessment will be performed independently by two reviewers. The quality and risk of bias in the included studies will be assessed by using the Effective Public Health Practice Project tool. A narrative synthesis of the extracted data will be carried out, and for studies that are sufficiently homogenous, a meta-analysis using random-effects models will be performed.
This systematic review will provide a clearer picture of the epidemiology of heart failure after the treatment of childhood cancer. The collected data will be of value for future childhood cancer treatment protocols and will offer guidance for posttreatment cardiac surveillance among survivors.
PROSPERO CRD42021247622 . Registered on April 28, 2021. This protocol follows the structure of the recommendation of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P).
在过去的几十年中，儿童癌症的存活率有了很大的提高。然而，癌症治疗后发生晚期心脏并发症的风险仍然很高。先前的研究表明，儿童癌症幸存者发生心力衰竭的风险明显高于不同对照人群。本系统评价的目的是确定、批判性评价和综合现有基于人群的研究报告，这些研究报告了儿童癌症治疗后可能发生心力衰竭的频率，包括发病率和患病率。
将从其成立日期开始至 2021 年 5 月 17 日搜索以下数据库：MEDLINE、Embase、Scopus、CINAHL、CAB International、AMED、Global Health、PsycINFO、Web of Science 和 Google Scholar。将纳入报告任何类型儿童癌症治疗后心力衰竭发病率和/或患病率的基于人群的研究。文章筛选、数据提取和质量评估将由两名评审员独立进行。将使用有效公共卫生实践项目工具评估纳入研究的质量和偏倚风险。将对提取的数据进行叙述性综合，对于足够同质的研究，将使用随机效应模型进行荟萃分析。
本系统评价将更清楚地了解儿童癌症治疗后心力衰竭的流行病学。收集的数据将对未来的儿童癌症治疗方案有价值，并为幸存者的治疗后心脏监测提供指导。
PROSPERO CRD42021247622。于 2021 年 4 月 28 日注册。本方案遵循系统评价和荟萃分析方案的首选报告项目（PRISMA-P）建议的结构。
